• HOME
• Maternal Child
  • Maternal Child Home
  • Breastfeeding
  • Family Planning
  • Child Health Notes
  • OB/GYN CCC Corner
  • Perinatologist Corner
  • Pregnancy
• Female Health Systems
  • FHS Home Page
  • Access to Care
  • ACOG/IHS Course
  • Advanced Practice Nurses & PA(s)
  • APN/PA(s) Links
  • Conferences
  • Cultural Appropriateness
  • Discussion Groups
  • Evidence Based Practice
  • Forms
  • Helpful Links
  • Job Opportunities
  • Meeting Lecture Notes
  • Newsletters and Journals
  • Patient Education
  • Primary Care Discussion Forum
  • Programs, Databases and Resources
  • Training
• Women's Health
  • Women's Health Home Page
  • Cancer
  • Cardiovascular Disease
  • Diabetes
  • Mature Women
  • Mental Health
  • Sexually Transmitted Infections
  • Substance Abuse
• Violence Against Native Women
  • VANW Home Page
  • Clinical Tools
  • Community Action
  • Current Events
  • Legislative Action
  • Other Links
  • Patient Education
  • Policies and Procedures
  • Provider Education
  • Public Health
  • Resources
  • Sexual Assault

• Maternal Child Topics
  • Maternal Child Home
  • Breastfeeding
  • Family Planning
  • Child Health Notes
  • OB/GYN CCC Corner
  • Perinatologist Corner
  • Pregnancy

Maternal Child

Perinatologist Corner - C.E.U/C.M.E. Modules

Antibody Screen Positive: Rh Disease and Other Atypical Antibodies

Sponsored by The Indian Health Service Clinical Support Center

13. Rh Disease and Other Atypical Antibodies

Step 13. Other on-line resources

AHRQ: U.S. Preventive Services Task Force

Summary of Recommendations

• The U.S. Preventive Services Task Force (USPSTF) strongly recommends Rh (D) blood typing and antibody testing for all pregnant women during their first visit for pregnancy-related care.
  Rating: A Recommendation
  Rationale : The USPSTF found good evidence that Rh (D) blood typing, anti-Rh (D) antibody testing, and intervention with Rh (D) immunoglobulin, as appropriate, prevents maternal sensitization and improves outcomes for newborns. The benefits substantially outweigh any potential harms.
• The USPSTF recommends repeated Rh (D) antibody testing for all unsensitized Rh (D)-negative women at 24-28 weeks' gestation, unless the biological father is known to be Rh (D)-negative.
  Rating: B Recommendation
  Rationale : The USPSTF found fair evidence that repeated antibody testing for unsensitized Rh (D)-negative women (unless the father is also known to be Rh [D]-negative) and intervention with Rh (D) immunoglobulin, as appropriate, provides additional benefit over a single test at the first prenatal visit in preventing maternal sensitization and improving outcomes for newborns. The benefits of repeated testing substantially outweigh any potential harms.

The USPSTF found no new evidence addressing the role of screening, new screening tests, new treatment protocols, or potential harms associated with screening and treatment of Rh (D) incompatibility. However, there is pre-existing good evidence for the efficacy and effectiveness of blood typing, anti-Rh (D) antibody screening, and postpartum Rh (D) immunoglobulin prophylaxis.

National Guidelines Clearinghouse
Search by Rh Disease

PubMed
Search by Rh Isoimmunization or Rh Disease

Geneva Federation for Medical Education and Research – Rh Isoimmunization

ObFocus.com – Management of Isoimmunization

12. I. H. S. on-line resources‹ Previous | Next › 14. ACOG Resources

Return to top of page